newsfilter
← Latest News
GlobeNewswire·

Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures

-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical remission by Modified Mayo